查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029年全球地中海貧血症市場規模研究與預測，按治療類別（鐵螯合藥物）、按管道（基因治療）和區域分析。
市場調查報告書
商品編碼
1269584

2022-2029年全球地中海貧血症市場規模研究與預測，按治療類別（鐵螯合藥物）、按管道（基因治療）和區域分析。

Global Thalassemia Market Size study & Forecast, by Therapeutic Class (Iron Chelating Drugs), by Pipeline (Gene Therapy) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021年，全球地中海貧血症市場價值約為25.8億美元，預計在2022-2029年的預測期內將以超過5%的健康成長率成長。根據美國疾病控制和預防中心（Centers for Disease Control and Prevention）的說法- 地中海貧血症定義為一種遺傳性血液疾病，當身體不能製造足夠的血紅蛋白時引起。血紅蛋白是紅血球的一個重要組成部分。地中海貧血是一種可治療的疾病，透過輸血和螯合療法可以得到很好的控制。與地中海貧血有關的體徵和症狀有不同類型，包括疲勞。虛弱，皮膚蒼白或發黃，面部骨骼畸形，生長緩慢，腹部腫脹，以及尿液發黑等等。血液病發病率的增加和擴大採用輸血和鐵螯合療法是推動市場成長的關鍵因素。

血液病患病率的增加有助於全球地中海貧血症市場的成長。例如，根據印度兒科學會（IPA）的估計，截至2021年，全球受地中海貧血影響的兒童總發病率中約有10%，每8個地中海貧血攜帶者中就有1個生活在印度。此外，根據世界衛生組織（WHO）的估計- β-地中海貧血症影響了世界人口的2.9%。另外，發展中地區不斷成長的醫療保健產業和越來越多的血液疾病臨床試驗將在預測期內為市場創造有利的成長前景。然而，在2022-2029年的預測期內，與地中海貧血症治療相關的高成本抑制了市場成長。

全球地中海貧血症市場研究的主要地區包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於地中海貧血症的發病率不斷增加，以及該地區衛生基礎設施的支出增加，北美在收入方面主導了市場。而亞太地區在預測期內預計將以最高的年複合成長率成長，原因是諸如老年人和目標人群的增加，血液相關疾病發病率的成長，以及契約製造組織在該地區的快速擴張。

該研究的目的是確定近年來不同領域和國家的市場規模，並對未來幾年的價值進行預測。本報告旨在將研究涉及的國家內的產業的品質和數量方面都涵蓋其中。

本報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來成長。此外，還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。

目錄

第一章：執行摘要

  • 市場簡介
  • 2019-2029年全球及細分市場的估計和預測
    • 2019-2029年地中海貧血症市場，按地區分類
    • 2019-2029年地中海貧血症市場，按治療類別分類
    • 2019-2029年地中海貧血症市場，按管線分類
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球地中海貧血症市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 研究的範圍
    • 產業發展
  • 研究涵蓋的年份
  • 貨幣兌換率

第三章：全球地中海貧血症市場動態

  • 地中海貧血症市場影響分析（2019-2029）。
    • 市場驅動力
      • 血液疾病的發病率越來越高
      • 擴大採用輸血和鐵螯合療法
    • 市場挑戰
      • 與地中海貧血症治療有關的高成本
    • 市場機會
      • 發展中地區的醫療保健產業不斷成長
      • 血液疾病的臨床試驗越來越多

第四章：全球地中海貧血症市場產業分析

  • 波特五力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力模型的未來方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 經濟
    • 社會
    • 技術
  • 最佳投資機會
  • 最佳策略
  • 產業專家展望
  • 分析師建議和結論

第五章：風險評估：COVID-19的影響

  • 評估COVID-19對產業的整體影響
  • COVID-19前和COVID-19後的市場情況

第六章：全球地中海貧血症市場，按治療類別分類

  • 市場簡介
  • 按治療類別分類的全球地中海貧血症市場，性能-潛力分析
  • 2019-2029年全球地中海貧血症市場按治療類別的估計和預測
  • 地中海貧血症市場，細項分析
    • 鐵質螯合藥物

第7章：全球地中海貧血症市場，按管線分類

  • 市場簡介
  • 全球地中海貧血症市場的管線、性能- 潛力分析
  • 2019-2029年全球地中海貧血症市場按管道的估計和預測
  • 地中海貧血症市場，次級細分市場分析
    • 基因治療

第八章：全球地中海貧血症市場，區域分析

  • 地中海貧血症市場，區域市場簡介
  • 北美洲
    • 美國
      • 2019-2029年治療類別細分估計和預測
      • 2019-2029年管線分類估計和預測
    • 加拿大
  • 歐洲地中海貧血症市場簡介
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區地中海貧血症市場簡介
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲地中海貧血症市場簡介
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 世界其他地區

第九章：競爭情報

  • 頂級市場戰略
  • 公司簡介
    • Bluebird Bio Inc.
      • 關鍵資訊
      • 概況
      • 財務（取決於資料的可用性）
      • 產品摘要
      • 近期發展情況
    • Acceleron Pharma, Inc.
    • Celgene Corporation
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Gamida Cell
    • Kiadis Pharma
    • La Jolla Pharmaceutical Company
    • IONIS Pharmaceuticals
    • Novartis AG

第十章：研究過程

  • 研究過程
    • 資料探勘
    • 資料分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Thalassemia Market is valued approximately USD 2.58 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2022-2029. According to Centers for Disease Control and Prevention - Thalassemia can be defined as an inherited blood disorder caused when the body doesn't make enough hemoglobin. Hemoglobin is an important part of red blood cells. Thalassemia is a treatable disorder that can be well-managed with blood transfusions and chelation therapy. There are different types of signs and symptoms associated with thalassemia including Fatigue. Weakness, Pale or yellowish skin, Facial bone deformities, Slow growth, Abdominal swelling., and Dark urine among others. The increasing prevalence of blood disorders and growing adoption of blood transfusion and iron chelation therapies are key factors driving the market growth.

The increasing prevalence of blood disorders is contributing towards the growth of the Global Thalassemia Market. For instance - according to Indian Academy of Pediatrics (IPA) estimates - as of 2021, approximately 10% of the total world incidence of thalassemia-affected children and one in eight of thalassemia carriers live in India. Additionally, as per World Health organization (WHO) estimates - Beta-thalassemia affects 2.9% of the world's population. Also, growing healthcare industry in developing regions and increasing number of clinical trials for blood disorders would create lucrative growth prospectus for the market over the forecast period. However, the high cost associated with Thalassemia treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Thalassemia Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the growing incidences of thalassemia and rise in spending in health infrastructure in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing incidences of blood related disorders as well as rapid expansion of contract manufacturing organizations in the region.

Major market player included in this report are:

  • Bluebird Bio Inc.
  • Acceleron Pharma, Inc.
  • Celgene Corporation
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Gamida Cell
  • Kiadis Pharma
  • La Jolla Pharmaceutical Company
  • IONIS Pharmaceuticals
  • Novartis AG

Recent Developments in the Market:

  • In August 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy intended for the treatment of adult and pediatric patients affected by beta-thalassemia.

Global Thalassemia Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Therapeutic Class, Pipeline, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Therapeutic Class:

  • Iron Chelating Drugs

By Pipeline:

  • Gene Therapy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Thalassemia Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Thalassemia Market, by Therapeutic Class, 2019-2029 (USD Billion)
    • 1.2.3. Thalassemia Market, by Pipeline, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Thalassemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Thalassemia Market Dynamics

  • 3.1. Thalassemia Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of blood disorders
      • 3.1.1.2. Growing adoption of blood transfusion and iron chelation therapies
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost associated with treatment of Thalassemia
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing healthcare industry in developing regions
      • 3.1.3.2. Increasing number of clinical trials for blood disorders

Chapter 4. Global Thalassemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Thalassemia Market, by Therapeutic Class

  • 6.1. Market Snapshot
  • 6.2. Global Thalassemia Market by Therapeutic Class, Performance - Potential Analysis
  • 6.3. Global Thalassemia Market Estimates & Forecasts by Therapeutic Class 2019-2029 (USD Billion)
  • 6.4. Thalassemia Market, Sub Segment Analysis
    • 6.4.1. Iron Chelating Drugs

Chapter 7. Global Thalassemia Market, by Pipeline

  • 7.1. Market Snapshot
  • 7.2. Global Thalassemia Market by Pipeline, Performance - Potential Analysis
  • 7.3. Global Thalassemia Market Estimates & Forecasts by Pipeline 2019-2029 (USD Billion)
  • 7.4. Thalassemia Market, Sub Segment Analysis
    • 7.4.1. Gene Therapy

Chapter 8. Global Thalassemia Market, Regional Analysis

  • 8.1. Thalassemia Market, Regional Market Snapshot
  • 8.2. North America Thalassemia Market
    • 8.2.1. U.S. Thalassemia Market
      • 8.2.1.1. Therapeutic Class breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Pipeline breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Thalassemia Market
  • 8.3. Europe Thalassemia Market Snapshot
    • 8.3.1. U.K. Thalassemia Market
    • 8.3.2. Germany Thalassemia Market
    • 8.3.3. France Thalassemia Market
    • 8.3.4. Spain Thalassemia Market
    • 8.3.5. Italy Thalassemia Market
    • 8.3.6. Rest of Europe Thalassemia Market
  • 8.4. Asia-Pacific Thalassemia Market Snapshot
    • 8.4.1. China Thalassemia Market
    • 8.4.2. India Thalassemia Market
    • 8.4.3. Japan Thalassemia Market
    • 8.4.4. Australia Thalassemia Market
    • 8.4.5. South Korea Thalassemia Market
    • 8.4.6. Rest of Asia Pacific Thalassemia Market
  • 8.5. Latin America Thalassemia Market Snapshot
    • 8.5.1. Brazil Thalassemia Market
    • 8.5.2. Mexico Thalassemia Market
    • 8.5.3. Rest of Latin America Thalassemia Market
  • 8.6. Rest of The World Thalassemia Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Bluebird Bio Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Acceleron Pharma, Inc.
    • 9.2.3. Celgene Corporation
    • 9.2.4. GlaxoSmithKline plc
    • 9.2.5. Incyte Corporation
    • 9.2.6. Gamida Cell
    • 9.2.7. Kiadis Pharma
    • 9.2.8. La Jolla Pharmaceutical Company
    • 9.2.9. IONIS Pharmaceuticals
    • 9.2.10. Novartis AG

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Thalassemia Market, report scope
  • TABLE 2. Global Thalassemia Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Thalassemia Market estimates & forecasts by Therapeutic Class 2019-2029 (USD Billion)
  • TABLE 4. Global Thalassemia Market estimates & forecasts by Pipeline 2019-2029 (USD Billion)
  • TABLE 5. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Thalassemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Thalassemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Thalassemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Thalassemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Thalassemia Market
  • TABLE 70. List of primary sources, used in the study of global Thalassemia Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Thalassemia Market, research methodology
  • FIG 2. Global Thalassemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Thalassemia Market, key trends 2021
  • FIG 5. Global Thalassemia Market, growth prospects 2022-2029
  • FIG 6. Global Thalassemia Market, porters 5 force model
  • FIG 7. Global Thalassemia Market, pest analysis
  • FIG 8. Global Thalassemia Market, value chain analysis
  • FIG 9. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Thalassemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Thalassemia Market, regional snapshot 2019 & 2029
  • FIG 15. North America Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Thalassemia Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Thalassemia Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable